Regeneron Pharmaceuticals, Inc.

Other

Scott Mellis

Margaret Karow

Joanne Papadopoulos

Catherine Vicary

George D Yancopoulos

Neil E Stahl

Allen Radin

William J Sasiela

Gary Swergold

Steven P Weinstein

Gary Herman

Eduardo Forleo Neto

Denise Calaprice

Dinko Gonzalez Trotter

Andrew Rankin

Aristides Economides

Methods for treating fibrodysplasia ossificans progressiva (FOP) in human subjects are provided. Such methods involve administering to a subject having FOP a therapeutically effective amount of an activin A antagonist, such as an antibody against activin A.

Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

Methods of treating, inhibiting, or ameliorating an autoinflammatory disorder, disease, or condition in a subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the autoinflammatory disorder, disease, or condition is treated, inhibited, or ameliorated. The IL-1 antagonist is a molecule capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult or child suffering from Neonatal Onset Multisystem Inflammatory Disorder (NOMID/CINCA), Muckle-Wells Syndrome (MWS), Familial Cold Autoinflammatory Syndrome (FCAS), familial mediterranean fever (FMF), tumor necrosis factor receptor-associated periodic fever syndrome (TRAPS), or systemic onset juvenile idiopathic arthritis (Still's Disease).

Methods of using IL-1 antagonists to treat autoinflammatory disease

Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.

Use of IL-1 antagonists to treat gout

Methods of treating, inhibiting, or ameliorating arthritis, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, or juvenile rheumatoid arthritis, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein arthritis inhibited, or ameliorated. The IL-1 antagonist is an IL-1-specific fusion protein comprising an IL-1 binding portion of the extracellular domain of human II-1RAcP, an IL-1 binding portion of the extracellular domain of human IL-1RI, and a multimerizing component antagonist, preferably comprising a sequence selected from the group consisting of SEQ ID NO:4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, or a substantially identical sequence.

Use of an IL-1 antagonist for treating arthritis

Methods of identifying human subjects for treatment of obesity or an obesity-related condition with ciliary neurotrophic factor (CNTF) or a CNTF-related molecule, such as Axokine&#xae;, based on the presence of human leukocyte antigen (HLA) DR&#x3b2;1 allele 1501 or the absence of HLA DR&#x3b2;1 allele 0701.

Methods for identifying a candidate for treatment of obesity

Growing community of inventors

New Rochelle, NY, United States of America

Scott Mellis